Pharmaron Holds Hoddesdon UK Opening Ceremony and Symposium on Synthetic and Medicinal Chemistry

Feb. 10, 2017, UK – Pharmaron has completed the acquisition of the Hoddesdon UK facility from Merck Sharpe & Dohme Limited (MSD), which includes MSD’s process research and development facility.

To recognize the company expansion in the UK, an opening ceremony and symposium was held. The symposium, which included world-class guest speakers from academia and the life science industry, reflects Pharmaron’s long-term commitment to excellence in science.

Presenters included Prof. John Blacker, University of Leeds, Dr. James Bull, Imperial College London, Prof. Darren Dixon, University of Oxford, Dr. Rich Tillyer, MSD, Dr. David Wilson, AstraZeneca and Prof. Shu-Li You, Shanghai Institute of Organic Chemistry.  The presentations focused on state-of-art achievements in synthetic and medicinal chemistry.

The opening of the Pharmaron Hoddesdon site in the UK is part of Pharmaron’s vision to be a global leader in the small molecule based drug R&D service industry and its mission to support the success of partners in discovery, development and commercialization of innovative drugs.

Boliang Lou, Chairman and CEO of Pharmaron commented, “It is an honor to have key opinion leaders from the industry and academia present in our symposium, as well as be here for our Hoddesdon site opening ceremony. I am excited to expand our process chemistry capabilities in Europe with a world-class platform already in place. This allows us to tap into the UK talent pool and set a footprint in Europe and further strengthen our R&D service capabilities.  We will continue to enhance our capability and capacity in the Hoddesdon site to serve our partners better.”